手术等待时间与延迟对肾细胞癌肿瘤学结局的影响
本研究基于加拿大肾癌信息系统多中心前瞻性队列,纳入2011至2019年临床分期≥T1b的肾细胞癌患者1769例,评估手术等待时间与病理升级、复发、癌特异性生存和总生存的关联。中位等待时间整体为54天,cT1b为81天,cT2为45天,cT3/4为35天。调整混杂因素后,延长等待时间与肿瘤复发或死亡无关联,在2年随访中等待至24周未与不良肿瘤学结局相关。
要点
- 肾癌手术中位等待时间整体54天,cT1b肿瘤较长(81天),cT3/4较短(35天)。
- 调整混杂因素后,延长等待时间与肿瘤复发或死亡无显著关联。
- 在当前外科分诊实践下,等待至24周未观察到不良肿瘤学结局。
核心结论
- 在现行外科分诊实践下,肾细胞癌手术等待时间延长至24周与2年随访内的不良肿瘤学结局无关。
研究设计与样本
- 加拿大肾癌信息系统(CKCis)多中心前瞻性队列,纳入2011年1月至2019年12月诊断的临床分期≥T1b肾细胞癌患者1769例。
主要发现
- 整体队列中位手术等待时间为54天(IQR 29-86)。
- cT1b肿瘤(1166例)中位等待81天(IQR 49-127),cT2(672例)为45天(IQR 27-71),cT3/4(563例)为35天(IQR 18-61)。
- 调整合并症、肿瘤大小、分级、组织学亚型、切缘状态和病理分期后,延长等待时间与癌症复发或死亡无关联。
临床怎么用
- 对于临床局限性或局部进展性肾细胞癌,在合理分诊下手术等待至24周未显示增加复发或死亡风险,可据此缓解患者和医生的焦虑。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: The time between radiographic identification of a renal tumor and surgery can be concerning for patients and clinicians due to fears of tumor progression while awaiting treatment. This study aimed to evaluate the association between surgical wait time and oncologic outcomes for patients with renal cell carcinoma. MATERIALS AND METHODS: The Canadian Kidney Cancer Information System is a multi-institutional prospective cohort initiated in January 2011. Patients with clinical stage T1b or greater renal cell carcinoma diagnosed between January 2011 and December 2019 were included in this analysis. Outcomes of interest were pathological up staging, cancer recurrence, cancer specific survival and overall survival. Time to recurrence and death were estimated using Kaplan-Meier estimates and associations were determined using Cox proportional hazards models. RESULTS: A total of 1,769 patients satisfied the study criteria. Median wait times were 54 days (IQR 29-86) for the overall cohort and 81 days (IQR 49-127) for cT1b tumors (1,166 patients), 45 days (IQR 27-71) for cT2 tumors (672 cases) and 35 days (IQR 18-61) for cT3/4 tumors (563). Adjusting for comorbidity, tumor size, grade, histological subtype, margin status and pathological stage, there was no association between prolonged wait time and cancer recurrence or death. CONCLUSIONS: In the context of current surgeon triaging practices surgical wait times up to 24 weeks were not associated with adverse oncologic outcomes after 2 years of followup.
引用
- Shiff B, Breau RH, Patel P, et al. Impact of Time to Surgery and Surgical Delay on Oncologic Outcomes for Renal Cell Carcinoma. J Urol. 2020. PMID: 32614274. doi:10.1097/JU.0000000000001230
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。